
1. vaccine. 2011 jun 10;29(26):4308-15. doi: 10.1016/j.vaccine.2011.04.028. epub
2011 apr 21.

worldwide sequence conservation transmission-blocking vaccine candidate pvs230
in plasmodium vivax.

doi m(1), tanabe k, tachibana s, hamai m, tachibana m, mita t, yagi m, zeyrek fy,
ferreira mu, ohmae h, kaneko a, randrianarivelojosia m, sattabongkot j, cao ym,
horii t, torii m, tsuboi t.

author information: 
(1)cell-free science technology research center, ehime university, matsuyama,
ehime 790-8577, japan.

pfs230, surface protein gametocyte/gamete human malaria parasite,
plasmodium falciparum, prime candidate malaria transmission-blocking
vaccine. plasmodium vivax ortholog pfs230 (pvs230), however, 
been study aspects pvs230 date. investigate whether pvs230 can
be vivax malaria transmission-blocking vaccine, performed evolutionary and
population genetic analysis pvs230 gene (pvs230: pvx_003905). analysis
of pvs230 orthologs eight plasmodium species revealed two distinctive 
parts: interspecies variable part (ivp) containing species-specific
oligopeptide repeats n-terminus 7.5kb interspecies conserved part
(icp) containing 14 cysteine-rich domains. pvs230 closely related its
orthologs, pks230 pcys230, monkey malaria parasites. analysis 113
pvs230 sequences obtained worldwide, showed nucleotide diversity is
remarkably low non-repeat 8-kb region pvs230 (θπ=0.00118) 77
polymorphic nucleotide sites, 40 results amino acid replacements. a
signature purifying selection balancing selection seen on
pvs230. functional and/or structural constraints may limit level of
polymorphism pvs230. observed limited polymorphism pvs230 ground
for utilization pvs230 effective transmission-blocking vaccine.

copyright © 2011 elsevier ltd. rights reserved.

doi: 10.1016/j.vaccine.2011.04.028 
pmcid: pmc3130600
pmid: 21514344  [indexed medline]

